Vistagen Therapeutics, Inc.: Commodore Capital LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Commodore Capital LP amended its Schedule 13G filing on Vistagen Therapeutics, Inc., disclosing a change in its passive stake in the company under SEC accession number 0001831942-26-000051. The filing reflects the investment firm's updated ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed when an investor's beneficial ownership crosses certain thresholds or when previously reported holdings change materially. The update signals continued institutional interest in Vistagen, which develops therapies for anxiety and central nervous system disorders. Investors will watch for further 13G or 13D filings to gauge whether Commodore's position is growing or being trimmed.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Vistagen Therapeutics, Inc., Commodore Capital LP